1108 related articles for article (PubMed ID: 20123001)
1. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
[TBL] [Abstract][Full Text] [Related]
2. Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors.
Wang Z; Liu Q; Zhang R; Liu S; Xia Z; Hu Y
Neuroscience; 2009 Nov; 163(4):1363-72. PubMed ID: 19635525
[TBL] [Abstract][Full Text] [Related]
3. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
[TBL] [Abstract][Full Text] [Related]
4. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
[TBL] [Abstract][Full Text] [Related]
5. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Jakobsen B; Gramsbergen JB; Møller Dall A; Rosenblad C; Zimmer J
Eur J Neurosci; 2005 Jun; 21(11):2939-48. PubMed ID: 15978005
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of the neurotrophic effect of GDNF on DA neurons: role of protein kinase CK2.
Chao CC; Chiang CH; Ma YL; Lee EH
Neurobiol Aging; 2006 Jan; 27(1):105-18. PubMed ID: 16298246
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
12. Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.
Zhang Y; Xia Z; Hu Y; Orsi A; Rees D
FEBS Lett; 2008 Mar; 582(6):956-60. PubMed ID: 18298955
[TBL] [Abstract][Full Text] [Related]
13. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
14. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
15. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
16. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures.
Tian YY; An LJ; Jiang L; Duan YL; Chen J; Jiang B
Life Sci; 2006 Dec; 80(3):193-9. PubMed ID: 17049947
[TBL] [Abstract][Full Text] [Related]
17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
18. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
20. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
